Stocksigma LogoStocksigma Logo

Natco Pharma Launches Generic Carboplatin Injection in the US Market

NATCO Pharma Limited announced on 19th Oct'26 that its US subsidiary, NATCO Pharma USA LLC, has launched Carboplatin Injection (generic Paraplatin) in the

Natco Pharma Launches Generic Carboplatin Injection in the US Market

Natco Pharma Ltd 路 Press Release 路 19 Oct 2026, 7:55 pm

Natco Pharma Launches Generic Carboplatin Injection in the US Market NATCO Pharma Limited announced on 19th Oct'26 that its US subsidiary, NATCO Pharma USA LLC, has launched Carboplatin Injection (generic Paraplatin) in the US market in manufacturing collaboration with Chennai-based Teyro Labs Pvt Ltd. The oncology product addresses a critical US market shortage and is indicated for advanced ovarian carcinoma treatment. According to industry sales data, Carboplatin Injection generated estimated annual US sales of USD 27.8 million for the 12 months ending Jun'26.

Original exchange filing (PDF)

More announcements from Natco Pharma Ltd

All Natco Pharma Ltd announcements